Get the Stockscreener App
3.67
5.66%
-0.22
After Hours:
3.67
Precigen Inc stock is traded at $3.67, with a volume of 7.06M.
It is down -5.66% in the last 24 hours and down -3.17% over the past month.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
See More
Previous Close:
$3.89
Open:
$3.8
24h Volume:
7.06M
Relative Volume:
1.58
Market Cap:
$1.30B
Revenue:
$9.68M
Net Income/Loss:
$-250.64M
P/E Ratio:
-2.6218
EPS:
-1.3998
Net Cash Flow:
$-89.83M
1W Performance:
+11.89%
1M Performance:
-3.17%
6M Performance:
+4.56%
1Y Performance:
+123.78%
1-Day Range:
$3.62
$4.00
1-Week Range:
$3.04
$4.275
52-Week Range:
$1.11
$5.465
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen Inc
Sector
Industry
Phone
301-556-9900
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
3.67 | 1.30B | 9.68M | -250.64M | -89.83M | -1.3998 |
VRTX
Vertex Pharmaceuticals Inc
|
433.07 | 110.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
737.71 | 77.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
691.40 | 42.91B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
317.36 | 42.09B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
283.03 | 31.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-22-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-23-23 | Initiated | JP Morgan | Neutral |
| Nov-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-21 | Initiated | Stifel | Buy |
| Feb-22-21 | Initiated | Wells Fargo | Overweight |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| May-08-20 | Initiated | H.C. Wainwright | Buy |
View All
Precigen Inc Stock (PGEN) Latest News
Precigen gains after 2025 results on Papzimeos' outlook - MSN
Precigen (PGEN) Is Up 11.9% After PAPZIMEOS’ Launch Shifts Focus Toward Commercial Revenue Model - simplywall.st
Precigen, Inc. (PGEN) reports Q4 loss, lags revenue estimates - MSN
Precigen, Inc. (NASDAQ:PGEN) Q4 2025 earnings call transcript - MSN
Precigen (NASDAQ:PGEN) Stock Rating Upgraded by Wall Street Zen - marketbeat.com
HC Wainwright Has Positive Estimate for Precigen Q3 Earnings - marketbeat.com
Discover Precigen And 2 Other Insider-Favored Growth Stocks - Yahoo Finance
PGEN Stock Price, Quote & Chart | PRECIGEN INC (NASDAQ:PGEN) - chartmill.com
Is It Too Late To Consider Precigen (PGEN) After Its 145% One Year Surge? - Yahoo Finance
Precigen Earnings Call Signals Powerful Launch Momentum - TipRanks
Analyst Upgrade: Whats the beta of Precigen Inc stockMarket Weekly Review & Fast Gain Stock Tips - baoquankhu1.vn
Precigen: The Best Potential Blockbuster You've Never Heard Of (Your ENT Has) - Seeking Alpha
These Analysts Boost Their Forecasts On Precigen Following Q4 Results - Benzinga
Precigen (PGEN) Soars 26% Despite Missed Revenue Estimates - GuruFocus
Precigen (NASDAQ:PGEN) Shares Gap Up Following Analyst Upgrade - MarketBeat
Precigen (PGEN) Shares Surge on Positive Q1 Outlook Despite Earnings Miss - GuruFocus
Olaplex, Kodiak Sciences, Precigen And Other Big Stocks Moving Higher On Thursday - Benzinga
Precigen (NASDAQ:PGEN) Price Target Raised to $9.00 at Citizens Jmp - MarketBeat
PGEN: Analyst Jason N. Butler Raises Price Target to $9 | PGEN S - GuruFocus
H.C. Wainwright raises Precigen stock price target on sales growth - uk.investing.com
Precigen stock gains on Q1 2026 outlook (PGEN:NASDAQ) - Seeking Alpha
PGEN: HC Wainwright & Co. Raises Price Target to $10.00 | PGEN S - GuruFocus
H.C. Wainwright raises Precigen stock price target on sales growth By Investing.com - Investing.com India
Precigen (NASDAQ:PGEN) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Precigen, Inc. (NASDAQ:PGEN) Q4 2025 Earnings Call Transcript - Insider Monkey
Precigen (PGEN) Reports Strong Q4 2025 with PAPZIMEOS Launch - GuruFocus
Citizens raises Precigen stock price target on strong PAPZIMEOS sales - Investing.com UK
Citizens raises Precigen stock price target on strong PAPZIMEOS sales By Investing.com - Investing.com Australia
Precigen Achieves First Commercial Revenue in 2025 with FDA Approval and Strong US Launch of PAPZIMEOS for RRP - Minichart
Crude Oil Gains 4%; Commercial Metals Posts Mixed Q2 Results - Sahm
Precigen Inc. 2025 Annual Report: Papzimeos Launch, UltraCAR-T & AdenoVerse Platform, Clinical Pipeline, Risks, and Competitive Landscape 33 34 35 38 40 54 - Minichart
Beyond the Balance Sheet: What SWOT Reveals About Precigen Inc (PGEN) - GuruFocus
Precigen Inc (PGEN) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Expansion ... By GuruFocus - Investing.com Canada
Q3 2025 Precigen Inc Earnings Call Transcript - GuruFocus
Earnings call transcript: Precigen Inc. beats revenue expectations in Q4 2025 - au.investing.com
Precigen Inc (PGEN) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Expansion Amidst Challenges - GuruFocus
Precigen Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Precigen expects Q1 revenue to exceed $18M as PAPZIMEOS launch accelerates with broad US payer coverage - MSN
Precigen, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Precigen Q4 Earnings Call Highlights - Yahoo Finance
Precigen, Inc. (PGEN) Posts Fourth Quarter Loss, Misses Revenue Expectations - Bitget
PGEN: PAPZIMEOS launch accelerates revenue growth and adoption, with Q1 2026 revenue set to exceed $18M - TradingView
Earnings call transcript: Precigen Q4 2025 sees revenue surge, PAPZIMEOS gains traction By Investing.com - za.investing.com
PGEN: Papzimeos launch accelerates revenue growth, with Q1 2026 sales expected to surpass $18 million - TradingView
Precigen (PGEN) Q4 2025 Earnings Call Transcript - The Globe and Mail
Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Earnings call transcript: Precigen Inc. beats revenue expectations in Q4 2025 By Investing.com - za.investing.com
Earnings call transcript: Precigen Q4 2025 sees revenue surge, PAPZIMEOS gains traction - Investing.com UK
Precigen (NASDAQ:PGEN) Issues Earnings Results, Beats Expectations By $0.09 EPS - marketbeat.com
Precigen Inc (NASDAQ:PGEN) Stock Surges on Narrower Loss and Commercial Transition After FDA Approval - chartmill.com
Precigen 10-K: $9.68M Revenue, $(1.37) EPS on FY net loss - TradingView
Precigen Inc Stock (PGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Precigen Inc Stock (PGEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KIRK RANDAL J | Director |
Dec 22 '25 |
Sale |
4.18 |
1,900,036 |
7,942,150 |
341,189 |
3.03%
2.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):